<p>Electrochemical aptamer-based (E-AB) sensors enable the accurate measurement of target concentrations in complex matrices such as plasma or serum. However, to function effectively in these environments, the aptamers must resist nonspecific binding to proteins and other interferants. Many research literature and commercially available (“off-the-shelf”) aptamers, originally selected without consideration for biofluid compatibility, are prone to such nonspecific interactions, which diminish sensor output and compromise sensitivity. To address this challenge and expand the utility of existing aptamer sequences, we present a tunable, generalizable method to restore the EC<sub>50</sub> of E-AB sensors in plasma to levels comparable to those in buffer. We validate this approach using three therapeutically relevant small molecules: the antiretroviral emtricitabine (FTC), the antibiotic tobramycin, and the antimalarial hydroxyquinoline. Applying our method, we recovered EC<sub>50</sub> values of 11 ± 3 µM for FTC (buffer: 10.4 ± 0.6 µM), 281 ± 91 µM for tobramycin (buffer: 190 ± 16 µM), and 1.1 ± 0.6 µM for hydroxyquinoline (buffer: 900 ± 95 µM). This strategy should enable the broader application of published small-molecule-binding aptamers for biofluid measurements, regardless of their original selection conditions.</p><p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

General approach to achieving electrochemical aptamer-based sensor sensitivity of buffer in blood plasma

  • Erin Demek,
  • Netzahualcóyotl Arroyo-Currás

摘要

Electrochemical aptamer-based (E-AB) sensors enable the accurate measurement of target concentrations in complex matrices such as plasma or serum. However, to function effectively in these environments, the aptamers must resist nonspecific binding to proteins and other interferants. Many research literature and commercially available (“off-the-shelf”) aptamers, originally selected without consideration for biofluid compatibility, are prone to such nonspecific interactions, which diminish sensor output and compromise sensitivity. To address this challenge and expand the utility of existing aptamer sequences, we present a tunable, generalizable method to restore the EC50 of E-AB sensors in plasma to levels comparable to those in buffer. We validate this approach using three therapeutically relevant small molecules: the antiretroviral emtricitabine (FTC), the antibiotic tobramycin, and the antimalarial hydroxyquinoline. Applying our method, we recovered EC50 values of 11 ± 3 µM for FTC (buffer: 10.4 ± 0.6 µM), 281 ± 91 µM for tobramycin (buffer: 190 ± 16 µM), and 1.1 ± 0.6 µM for hydroxyquinoline (buffer: 900 ± 95 µM). This strategy should enable the broader application of published small-molecule-binding aptamers for biofluid measurements, regardless of their original selection conditions.